CD8A and non-small cell lung carcinoma: Our observations are in line with a study in non-small cell lung cancer patients treated with PD-1 inhibitor therapy, in which responding patients showed higher numbers of PD-1+CD8+-expressing T cells during the first four weeks of treatment, supporting a predictive role of PD-1 expression for ICI treatment [20].